Odonate Therapeutics (ODT) IPO Opens Modestly Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends up on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Odonate Therapeutics Announces Pricing of Initial Public Offering
December 6, 2017 8:55 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Odonate Therapeutics, Inc. (the Company or Odonate), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $24.00 per share for aggregate gross proceeds of approximately $150 million. All of the shares of common stock are being offered by Odonate. In addition, Odonate has granted the underwriters a 30-day option to purchase up to 937,500 additional shares of its common stock at the initial public offering price,... More
